title: Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate.
abstract: Sweet's syndrome (acute febrile neutrophilic dermatosis) is characterized by an acute onset of erythematous plaques, fever, and leukocytosis. This syndrome has been reported to be associated with leukemia including chronic myelogenous leukemia (CML). Sweet's syndrome seen in patients with leukemia is usually associated with active and/or refractory disease. Imatinib Mesylate (STI-571, Gleevec) is widely used for therapy of CML. In this case report, CML cell infiltration of the skin was documented by fluorescence in situ hybridization (FISH) analysis in a patient with chronic-phase CML on Imatinib Mesylate (STI-571, Gleevec), who was at the time in molecular remission.
authors.affiliation: New York Medical College and Zalmen A. Arlin Cancer Institute, Room 250, Munger Pavilion, Valhalla, NY 10595, USA. delong_liu@nymc.edu
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
authors.forename: Karen
authors.initials: K
authors.lastname: Seiter
authors.forename: Thomas
authors.initials: T
authors.lastname: Mathews
authors.forename: Cecily J
authors.initials: CJ
authors.lastname: Madahar
authors.forename: Tauseef
authors.initials: T
authors.lastname: Ahmed
mesh_terms: D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications / Q000473:pathology*; D017254:Leukemic Infiltration / Q000175:diagnosis*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D012867:Skin / Q000473:pathology; D016463:Sweet Syndrome / Q000209:etiology* / Q000473:pathology
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate